Fluphenazine-induced acute and tardive dyskinesias in monkeys
dc.contributor.author | Domino, Edward F. | en_US |
dc.contributor.author | Kovacic, Beverly | en_US |
dc.date.accessioned | 2006-09-11T17:46:32Z | |
dc.date.available | 2006-09-11T17:46:32Z | |
dc.date.issued | 1984-09 | en_US |
dc.identifier.citation | Kovacic, Beverly; Domino, Edward F.; (1984). "Fluphenazine-induced acute and tardive dyskinesias in monkeys." Psychopharmacology 84(3): 310-314. <http://hdl.handle.net/2027.42/46432> | en_US |
dc.identifier.issn | 0033-3158 | en_US |
dc.identifier.issn | 1432-2072 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46432 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=6440175&dopt=citation | en_US |
dc.description.abstract | Five Cebus apella monkeys were treated with biweekly injections of fluphenazine enanthate (0.1–3.2 mg/kg IM). Three of these completed 1 full year of treatment, one injured its leg after 6 months of treatment and was killed, and another died of unknown causes after 9 months of treatment. All monkeys displayed abnormal movements corresponding to the early appearing extrapyramidal symptoms of neuroleptic-treated patients. These consisted initially of slowing or absence of volitional movement, trembling of the hands, trembling of the entire body, and general drowsy behavior. As treatment progessed, a variety of abnormal postures and movements appeared after each injection that were not exacerbated by drug withdrawal and, as tested at the end of the year, could be abolished or prevented with benztropine mesylate (0.2–0.5 mg/kg IM). The three monkeys that completed 1 year of treatment with fluphenazine were then withdrawn from the drug. After withdrawal, all three developed movements similar in appearance to those of patients with tardive dyskinesia (TD). Reinstitution of fluphenazine treatment, as tested in one monkey, abolished all movements resembling TD. | en_US |
dc.format.extent | 573279 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Cebus Apella | en_US |
dc.subject.other | Extrapyramidal Symptoms | en_US |
dc.subject.other | Dyskinesia | en_US |
dc.subject.other | Psychiatry | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Primates | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Fluphenazine Enanthate | en_US |
dc.subject.other | Dystonia | en_US |
dc.subject.other | Tardive Dyskinesia | en_US |
dc.title | Fluphenazine-induced acute and tardive dyskinesias in monkeys | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pharmacology, University of Michigan, 48109-0010, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Lafayette Clinic, Division of Pharmacology, 951 E. Lafayette, 48207, MI, Detroit, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 6440175 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46432/1/213_2004_Article_BF00555204.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00555204 | en_US |
dc.identifier.source | Psychopharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.